English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

A macromomycin (MCR)-resistant subline of mouse lymphoblastoma L5178Y cells was isolated after successive treatment of tumor-bearing mice with the antibiotic for 7 transplant generations, followed by cloning in culture in MCR-containing soft agar medium. The resistant cell line was about 17 times more resistant to MCR than was the parental cell line and exhibited cross-resistance to neocarzinostatin, mitomycin C and adriamycin in a similar degree to MCR. No significant cross-resistance was observed with aclarubicin, bleomycin and neothramycin. Alkaline phosphodiesterase activity in the plasma membrane of resistant cells was higher than that of parental cells. Uptake and efflux studies with [3H]adriamycin suggested that the resistance is due to decreased uptake and increased efflux of the antibiotic in resistant cells. Hybridization studies with MCR-sensitive and -resistant cells showed that the MCR resistance is a codominant trait in somatic cell hybrids.

Isolation, drug sensitivity, and some biochemical and genetical properties of macromomycin-resistant mouse lymphoblastoma L5178Y cells.